Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

Stephen O'Brien, MBBS, BSc, PhD MRCPath, MRCP, Leanne Cork, BSc, Valeria Bandeira, MD, Ruth Bescoby, MSc, Letizia Foroni, MD PhD, Lynn Alaily, MSc, RN, NDN, MICR, Wendy Osborne, MBBS, Helen Bell-Gorrod, BSc, Nicholas Latimer, PhD, Jane Apperley, MB ChB MD, Corinne Hedgley, BSc (Hons), Richard Syzdlo, PhD, Jennifer Byrne, MB, ChB, MRCP, MRCPath, MD, Christopher Pocock, MD PhD, Bernard Ramsahoye, MB, ChB, PhD FRCPath, MRCP, Thomas Zwingers, BSc, James Wason, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD

Blood (2018) 132 (Supplement 1): 457.

https://doi.org/10.1182/blood-2018-99-110128

Published: 2018

Journal Articles

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Mary Alikian, Rebecca Ellwood, Olga Tatarinova, Graham David Rose, George Nteliopoulos, Gareth Gerrard, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD, Alistair Reid, BSc, PhD, Letizia Foroni, MD PhD, Richard Clark, MBBS, MRCP, MRCPath, MD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2018-99-117616

Published: 2018

Journal Articles

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Simone Claudiani, MD, Jane Apperley, MB ChB MD, Afzal Khan, Richard Szydlo, PhD, George Nesr, MD, George Adams, MBChB, Letizia Foroni, MD PhD, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2018-99-119602

Published: 2018

Journal Articles

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

Louise Caldwell, BSc, Simone Claudiani, MD, Dragana Milojkovic, MBBS, PhD, Richard Szydlo, PhD, Elisabetta Abruzzese, MD, George Nesr, MD, Michael J. Mauro, MD, Renuka Palanicawander, MD, Aoife Gatenby, BSc, Ira Sabli, BSc, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1612.

https://doi.org/10.1182/blood.V130.Suppl_1.1612.1612

Published: 2017

Journal Articles

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Simone Claudiani, MD, Adi Shacham Abulafia, Ira Sabli, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1628.

https://doi.org/10.1182/blood.V130.Suppl_1.1628.1628

Published: 2017

Journal Articles

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Simone Claudiani, MD, Aoife Gatenby, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, Emily Ching, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1629.

https://doi.org/10.1182/blood.V130.Suppl_1.1629.1629

Published: 2017

Journal Articles

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Georgios Nteliopoulos, MSc, PhD, Alexandra Bazeos, MB, BS, MRCP, Gareth Gerrard, PhD, Simone Claudiani, MD, Ed Curry, PhD, Mary Alikian, MSc, PhD, Hui En Foong, Letizia Foroni, MD PhD FRCPath, Jane F. Apperley, MD

Blood (2016) 128 (22): 1223.

https://doi.org/10.1182/blood.V128.22.1223.1223

Published: 2016

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)

Jeeyune Bahk, BSc, Simone Claudiani, MD, Richard M Szydlo, BSc, PhD, Sarmad Toma, BSc, Faisal Abdillah, BSc, Sandra Hing, BSc, Simona Deplano, MDPhD, Dragana Milojkovic, Jane F Apperley, MD, Letizia Foroni, MD PhD

Blood (2015) 126 (23): 2795.

https://doi.org/10.1182/blood.V126.23.2795.2795

Published: 2015

Journal Articles

Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.

Gareth Gerrard, PhD, Mikel Valgañón, PhD, Hui En Foong, MSc, Dalia Kasperaviciute, PhD, Michael Müller, PhD, Laurence Game, PhD, Deena Iskander, MRCP, Irene Roberts, Letizia Foroni, MD, PhD, FRCPath, Josu de la Fuente, PhD, FRCP, MRCPCH, FRCPath, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 2369.

https://doi.org/10.1182/blood.V120.21.2369.2369

Published: 2012

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads to Earlier Engraftment and Higher Donor Chimerism Than Busulfan/Cyclophosphamide, and Enables the Use of Mismatched and Unrelated Donors for Transplantation in Haemoglobinopathies

Farah O'Boyle, PhD, Natalie Killeen, Mikel Valganon, BSc, Subarna Chakravorty, PhD, FRCPath, MRCPCH, Leena Karnik, FRCPath, Helen New, PhD, FRCP, FRCPath, Letizia Foroni, MD, PhD, Richard Szydlo, PhD, Irene Roberts, Josu de la Fuente, PhD, FRCP, MRCPCH, FRCPath

Blood (2012) 120 (21): 3234.

https://doi.org/10.1182/blood.V120.21.3234.3234

Published: 2012

Journal Articles

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

Blood (2011) 118 (21): 2535.

https://doi.org/10.1182/blood.V118.21.2535.2535

Published: 2011

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Dragana Milojkovic, MD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Amr R Ibrahim, Marco Bua, MD, Alistair Reid, PhD, Gareth Gerrard, PhD, Letizia Foroni, MD PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 3777.

https://doi.org/10.1182/blood.V118.21.3777.3777

Published: 2011

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

David Marin, Corinne Hedgley, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Letizia Foroni, MD PhD, Dragana Milojkovic, MD, Christopher Pocock, John M Goldman, Stephen O'Brien

Blood (2011) 118 (21): 785.

https://doi.org/10.1182/blood.V118.21.785.785

Published: 2011

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Amr R Ibrahim, Marco Bua, Jamshid S Khorshad, Dragana Milojkovic, Lina Eliasson, Richard Szydlo, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 2274.

https://doi.org/10.1182/blood.V116.21.2274.2274

Published: 2010

Journal Articles

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R Ibrahim, Dragana Milojkovic, Marco Bua, Jamshid S Khorshad, Richard Szydlo, Lina Eliasson, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 3414.

https://doi.org/10.1182/blood.V116.21.3414.3414

Published: 2010

NARROW

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)

Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads to Earlier Engraftment and Higher Donor Chimerism Than Busulfan/Cyclophosphamide, and Enables the Use of Mismatched and Unrelated Donors for Transplantation in Haemoglobinopathies

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only